Kenji Yasukawa - Astellas Pharma CEO Pres
| YPH Stock | EUR 10.02 0.23 2.35% |
Insider
Kenji Yasukawa is CEO Pres of Astellas Pharma
| Age | 63 |
| Phone | 81 3 3244 3000 |
| Web | https://www.astellas.com |
Astellas Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0653 % which means that it generated a profit of $0.0653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0898 %, meaning that it generated $0.0898 on every $100 dollars invested by stockholders. Astellas Pharma's management efficiency ratios could be used to measure how well Astellas Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Bruno Eschli | Roche Holding Ltd | N/A | |
| Sanjay Jariwala | Biogen Inc | N/A | |
| Nancy Grygiel | Amgen Inc | 55 | |
| Robert Decker | Johnson Johnson | 51 | |
| Christopher Viehbacher | Biogen Inc | 63 | |
| David Williams | Merck Co | 54 | |
| Stefan Oelrich | Bayer Aktiengesellschaft | 55 | |
| Peter Dannenbaum | Merck Co | N/A | |
| Frank Lohner | Amgen Inc | 54 | |
| Michael Preuss | Bayer Aktiengesellschaft | N/A | |
| Jonathan Graham | Amgen Inc | 62 | |
| Gabriel Harnier | Bayer Aktiengesellschaft | 52 | |
| Johannes MD | Roche Holding Ltd | 66 | |
| William Anderson | Roche Holding Ltd | 57 | |
| Michael CPA | Biogen Inc | 59 | |
| Jennifer Zachary | Merck Co | 45 | |
| Oliver Maier | Bayer Aktiengesellschaft | N/A | |
| Caroline Litchfield | Merck Co | 54 | |
| Jennifer Mauer | Merck Co | N/A | |
| James Swanson | Johnson Johnson | N/A | |
| Richard DeLuca | Merck Co | 60 | |
Management Performance
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 |
Astellas Pharma Leadership Team
Elected by the shareholders, the Astellas Pharma's board of directors comprises two types of representatives: Astellas Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Astellas. The board's role is to monitor Astellas Pharma's management team and ensure that shareholders' interests are well served. Astellas Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Astellas Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Minoru Kikuoka, CFO Officer | ||
| Naoki BSc, Chief VP | ||
| Kenji Yasukawa, CEO Pres | ||
| Stig Ogata, VP Communications | ||
| Katsuyoshi Sugita, Chief Officer | ||
| Chihiro Yokota, Devel Devel | ||
| Yoshitsugu Shitaka, Chief Officer | ||
| Nobue Yasuda, Gen Department | ||
| Catherine Levitt, G Counsel | ||
| Collette Taylor, VP HR |
Astellas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Astellas Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 24.85 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 50.33 % | |||
| Price To Earning | 29.54 X | |||
| Price To Book | 2.44 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Astellas Stock
Astellas Pharma financial ratios help investors to determine whether Astellas Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.